Skip to content

Study · Not a test of the peptide alone · 1987

4 results

Differentiation changes in cord blood T lymphocytes induced by synthetic C-terminal peptides of thymosin alpha 1.

Ho AD, Stehle B, Birr C, Heinzel W, Nebe TC

Thymus1 Jan 1987Cited by 3 (Europe PMC)

PMID3035761 (opens in a new tab)PepBankPUB-03035761

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin alpha-1.

  1. 01LabNot a test of Thymosin alpha-1 aloneIn vitro (cells)Activity measurement

    Thymosin alpha‑1 fragment 13-19 increased 5'NT activity in cord blood lymphocytes, with activity approximately equal to that of thymosin alpha‑1.

    In plain wordsIn cells, one piece of thymosin alpha‑1 raised an enzyme activity in newborn blood cells about as much as the whole peptide.

    Outcome
    Increase5'NT activity with fragment 13-19
    Study

    humann: not reported in source

    Cord blood T lymphocytes
    Comparator
    Parent peptide thymosin alpha 1
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    In the range of 1.3 X 10 to 1.3 X 10(-5)M, one of the eleven peptides examined (sequence 13-19) exhibited activity approximately equal to that of the parent peptide thymosin alpha 1: increase in activity of 5'NT (p less than 0.01) and reduction of cells positive for OKT4 (p less than 0.01).
    2 context sentences
    Summary · context
    In this study, the effects of these synthetic peptide fragments on cord blood T lymphocytes were studied.
    Summary · context
    After incubation with different peptide sequences, cord blood lymphocytes were analysed for surface antigenic markers (OKT4/OKT8) and for purine degradative enzymes (PNP, 5 NT).

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  2. 02LabNot a test of Thymosin alpha-1 aloneIn vitro (cells)Activity measurement

    Thymosin alpha‑1 fragment 13-19 reduced the number of OKT4-positive cord blood lymphocytes, with activity approximately equal to that of thymosin alpha‑1.

    In plain wordsIn cells, one piece of thymosin alpha‑1 lowered the share of OKT4-positive newborn blood cells about as much as the whole peptide.

    Outcome
    DecreaseOKT4-positive cells with fragment 13-19
    Study

    humann: not reported in source

    Cord blood T lymphocytes
    Comparator
    Parent peptide thymosin alpha 1
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    In the range of 1.3 X 10 to 1.3 X 10(-5)M, one of the eleven peptides examined (sequence 13-19) exhibited activity approximately equal to that of the parent peptide thymosin alpha 1: increase in activity of 5'NT (p less than 0.01) and reduction of cells positive for OKT4 (p less than 0.01).
    2 context sentences
    Summary · context
    In this study, the effects of these synthetic peptide fragments on cord blood T lymphocytes were studied.
    Summary · context
    After incubation with different peptide sequences, cord blood lymphocytes were analysed for surface antigenic markers (OKT4/OKT8) and for purine degradative enzymes (PNP, 5 NT).

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  3. 03LabNot a test of Thymosin alpha-1 aloneIn vitro (cells)Activity measurement

    Thymosin alpha‑1 fragment 20-28 increased 5'NT activity only.

    In plain wordsIn cells, a different piece of thymosin alpha‑1 raised one enzyme activity and changed nothing else that was measured.

    Outcome
    Increase5'NT activity with fragment 20-28
    Study

    humann: not reported in source

    Cord blood T lymphocytes
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    Another sequence (20-28) was able to induce an increase in 5'NT only and a third one (20-25) a reduction of cells positive for OKT4.
    2 context sentences
    Summary · context
    In this study, the effects of these synthetic peptide fragments on cord blood T lymphocytes were studied.
    Summary · context
    After incubation with different peptide sequences, cord blood lymphocytes were analysed for surface antigenic markers (OKT4/OKT8) and for purine degradative enzymes (PNP, 5 NT).

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  4. 04LabNot a test of Thymosin alpha-1 aloneIn vitro (cells)Activity measurement

    Thymosin alpha‑1 fragment 20-25 reduced the number of OKT4-positive cord blood lymphocytes.

    In plain wordsIn cells, a third piece of thymosin alpha‑1 lowered the share of OKT4-positive newborn blood cells.

    Outcome
    DecreaseOKT4-positive cells with fragment 20-25
    Study

    humann: not reported in source

    Cord blood T lymphocytes
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    Another sequence (20-28) was able to induce an increase in 5'NT only and a third one (20-25) a reduction of cells positive for OKT4.
    2 context sentences
    Summary · context
    In this study, the effects of these synthetic peptide fragments on cord blood T lymphocytes were studied.
    Summary · context
    After incubation with different peptide sequences, cord blood lymphocytes were analysed for surface antigenic markers (OKT4/OKT8) and for purine degradative enzymes (PNP, 5 NT).

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.